enzacamene

enzacamene

 [en″zah-kam´ēn]
an absorber of ultraviolet radiation, used topically as a sunscreen.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.
References in periodicals archive ?
Three additional items have been added since, namely, avobenzone (1-3%), ecamsule (up to 10%), and zinc oxide (2-25%) Table II: TEA Ingredients Ingredient TEA Date Docket Amiloxate 8/14/2002 FDA-2003-N-0196 Enzacamene 8/21/2002 FDA-2003-N-0196 Octyl Triazone 8/21/2002 FDA-2003-N-0196 Bemotrizinol 4/11/2005 FDA-2005-N-0453 Bisoctrizole 4/11/2005 FDA-2005-N-0453 Isocotrizinol 9/16/2005 FDA-2006-N-0314 Ecamsule 9/18/2007 FDA-2008-N-0474 Drometrizole Trisiloxane 1/21/2009 FDA-2003-N-0196
Those ingredients--amiloxate, enzacamene, octyl triazone, bemotrizinol, bisoctrizole, iscotrizinol, ecamsule and drometrizole trisiloxane--have been languishing on the Time and Extent Application list, awaiting FDA's approval for years; most of them waiting for a decade or longer!
These ingredients--amiloxate, enzacamene, octyl triazone, bemotrizinol, bisoctrizole, iscotrizinol, ecamsule and drometrizole trisiloxane--can already be found in sun care formulas throughout the world--with the exception of the US.
24, the agency sent the remaining two letters to the suppliers of ecamsule and enzacamene citing that their application was lacking the necessary data to support their safety and effectiveness.
But with the passage of The Sunscreen Innovation Act in January, formulators may eventually have as many as eight new ingredients to work with, including amiloxate, bemotrizinol, bisoctrizol, drometrizole trisiloxane, ecamsule, enzacamene, isocotrizinol and octly triazone--just don't expect these ingredients to show up on product labels anytime soon.
It began with the submission to the FDA of three ingredients (amiloxate, enzacamene and octly triazone) followed by the submission in 2005 of three additional ingredients (bemotrizinol, bisoctrizol and isocotrizinol), and finally, two L'Oreal ingredients (ecamsule in 2007 and drometrizole trisiloxane in 2009) were submitted to the FDA for approval for use in the USA under the TEA guidelines (See Table I).
Enzacamene is a camphor derivative that has received negative publicity in Europe.
These five ingredients are amiloxate, enzacamene, octyl triazone, bemotrizinol and bisoctrizol.
TABLE 1.: EUROPEAN INGREDIENTS UNDER FDA REVIEW Ingredient TEA Date Docket Amiloxate 8/14/2002 FDA-2003-N-0196 Enzacamene 8/21/2002 FDA-2003-N-0196 Octyl Triazone 8/21/2002 FDA-2003-N-0196 Bemotrizinol 4/11/2005 FDA-2005-N-0453 Bisoctrizole 4/11/2005 FDA-2005-N-0453 Isocotrizinol 9/16/2005 FDA-2006-O-0314 Ecamsule 9/18/2007 FDA-2008-N-0474 Drometrizole Trisiloxane 1/21/2009 FDA-2003-N-0196 As can be seen from the table above, three of those ingredients date back to 2002.
Amiloxate from Symrise, Enzacamene from EMD and Octyl triazone from BASF were submitted August 2002 and they were the first to receive a notice of eligibility (7/11/2003, 68FR41386).
They are: Amiloxate, Enzacamene, Octyl triazone, two Tinosorbs, Uvasorb and Ecamsule.